Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.725 USD | +1.21% | +0.69% | -11.77% |
Mar. 18 | Forte Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 05 | Camac Partners Provides Information to Shareholders | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 26.07M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 9 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.1% |
1 day | +1.21% | ||
1 week | +0.69% | ||
Current month | +4.14% | ||
1 month | +4.14% | ||
3 months | +2.10% | ||
6 months | +45.82% | ||
Current year | -11.77% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Wagner
CEO | Chief Executive Officer | 53 | 16-12-31 |
Anthony Riley
DFI | Director of Finance/CFO | 57 | 20-02-29 |
Chief Operating Officer | - | 20-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Gryska
BRD | Director/Board Member | 68 | 23-01-09 |
Steven Kornfeld
BRD | Director/Board Member | 56 | 20-05-31 |
Director/Board Member | 65 | 22-05-11 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 0.725 | +1.21% | 13,576 |
24-04-26 | 0.7163 | -3.07% | 5,789 |
24-04-25 | 0.739 | +2.65% | 2,845 |
24-04-24 | 0.7199 | -2.53% | 14,300 |
24-04-23 | 0.7386 | +2.58% | 4,701 |
Delayed Quote Nasdaq, April 29, 2024 at 04:30 pm EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-11.77% | 26.07M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- FBRX Stock